Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses by Slevin, Mark et al.
Angiogenic Oligosaccharides of Hyaluronan Induce Multiple
Signaling Pathways Affecting Vascular Endothelial Cell
Mitogenic and Wound Healing Responses*
Received for publication, October 1, 2001, and in revised form, August 22, 2002
Published, JBC Papers in Press, August 22, 2002, DOI 10.1074/jbc.M109443200
Mark Slevin‡§, Shant Kumar¶, and John Gaffney‡
From the ‡Department of Biological Sciences, Manchester Metropolitan University, Manchester M1 5GD, United Kingdom
and the ¶Department of Pathological Sciences, Stopford Building, Manchester Victoria University,
Manchester M1 5GD, United Kingdom
Hyaluronan (HA) is a large nonsulfated glycosamin-
oglycan and an important regulator of angiogenesis, in
particular, the growth and migration of vascular endo-
thelial cells. We have identified some of the key inter-
mediates responsible for induction of mitogenesis and
wound recovery. Treatment of bovine aortic endothelial
cells with oligosaccharides of hyaluronan (o-HA) re-
sulted in rapid tyrosine phosphorylation and plasma
membrane translocation of phospholipase C1 (PLC1).
Cytoplasmic loading with inhibitory antibodies to
PLC1, G, and Gi/o/t/z inhibited activation of extracel-
lular-regulated kinase 1/2 (ERK1/2). Treatment with the
Gi/o inhibitor, pertussis toxin, reduced o-HA-induced
PLC1 tyrosine phosphorylation, protein kinase C
(PKC)  and 1/2 membrane translocation, ERK1/2 acti-
vation, mitogenesis, and wound recovery, suggesting a
mechanism for o-HA-induced angiogenesis through G-
proteins, PLC1, and PKC. In particular, we demon-
strated a possible role for PKC in mitogenesis and
PKC1/2 in wound recovery. Using antisense oligonu-
cleotides and the Ras farnesylation inhibitor FTI-277,
we showed that o-HA-induced bovine aortic endothelial
cell proliferation, wound recovery, and ERK1/2 activa-
tion were also partially dependent on Ras activation,
and that o-HA-stimulated tyrosine phosphorylation of
the adapter protein Shc, as well as its association with
Sos1. Binding of Src to Shc was required for its activa-
tion and for Ras-dependent activation of ERK1/2, cell
proliferation, and wound recovery. Neither Src nor Ras
activation was inhibited by pertussis toxin, suggesting
that their activation was independent of heterotrimeric
G-proteins. However, the specific Src kinase inhibitor
PP2 inhibited G subunit co-precipitation with PLC1,
suggesting a possible role for Src in activation of PLC1
and interaction between two distinct o-HA-induced sig-
naling pathways.
Angiogenesis, the formation of new blood vessels, is essential
for the growth and repair of tissues and is prevalent in a
variety of pathological conditions. Excessive vascularization
occurs in rheumatoid arthritis, diabetic retinopathy, psoriasis,
and neoplasia (1, 2). Conversely, in myocardial infarction and
cerebrovascular diseases such as stroke, there is considerable
destruction of the vasculature (3). Further knowledge of the
mechanisms that regulate angiogenesis is required for the de-
velopment of strategies to control it.
Hyaluronan (HA)1 is a nonsulfated, linear glycosaminogly-
can, consisting of repeating units of (,1–4)-D-glucuronic acid-
(,1–3)-N-acetyl-D-glucosamine. HA is found in its native state
as a high molecular mass polymer (106 kDa) in the extracel-
lular matrix of almost all animal tissues and in significant
quantities in the skin (dermis and epidermis), brain, and cen-
tral nervous system (4). Apart from its role as an inert vis-
coelastic lubricant, essential for healthy joint function (5), HA
has a crucial role in regulation of the angiogenic process. In
particular, HA is a potent regulator of vascular endothelial cell
(EC) function. Native high molecular weight HA is anti-angio-
genic, inhibiting EC proliferation and migration (6–8) as well
as capillary formation in a three-dimensional collagen gel
model (9), whereas degradation products of specific size (3–10
disaccharide units; o-HA) stimulate EC proliferation (10–11),
migration (12), sprout formation (13), and result in angiogen-
esis in the chick chorioallantoic membrane (14) and in myocar-
dial infarction (15). Generation of this “angiogenic” o-HA from
the naturally occurring HA polymer is mediated by the en-
doglycosidase hyaluronidase (16), in association with tissue
damage, inflammatory disease, and in certain tumors (10, 16,
17). In addition, the degree of invasiveness and metastasis of
some tumors has been specifically linked to elevated HA ex-
pression (18–20). Hyaluronidase produced by tumor cells could
induce angiogenesis and be used by tumor cells as a “molecular
saboteur” to depolymerize HA to facilitate invasion (21). Hya-
luronan was intrinsically associated with metastasis in pros-
tate and bladder cancer (22–24) although high levels of o-HA
were shown in children with a bone-metastasizing variant of
renal tumor (25).
The biological functions of HA/o-HA are thought to be initi-
ated through cell surface receptors or HA-binding proteins,
resulting in signal transduction activation and ultimately mi-
togenesis (26–28). Native HA binds to a 34-kDa member of the
hyaladherins, and increases general protein tyrosine phospho-
rylation and that of PLC1 in a variety of cell lines, although
the role of this protein in mediating cell behavioral effects is
unknown (27). o-HA-induced Ras-dependent activation of mi-
togen-activated protein (MAP) kinase was shown in rat embry-
onic 3Y1 fibroblasts (29). In T24 bladder carcinoma cells, o-HA
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induced activation of NF-B via CD44 in a pathway involving
Ras, protein kinase C (PKC) , and a complex containing IB
kinase 1 and 2 (30). In vascular EC, both CD44 (31, 32) and
RHAMM (receptor for HA mediated motility) (33) have been
identified as potential targets for transduction of o-HA-induced
mitogenesis. Inhibition of the CD44/o-HA interaction using
anti-CD44 antibodies (J173) reduced proliferation and migra-
tion of calf pulmonary artery EC and human microvessel EC
(HMEC-1) (34). In three types of primary human EC, o-HA
bound to the RHAMM receptor and induced tyrosine phospho-
rylation of p125FAK, paxillin, and p42/44 extracellular signal-
regulated kinase (ERK1/2) resulting in cell proliferation (33).
We have previously demonstrated that o-HA but not native HA
induced up-regulation of the immediate early response genes
c-jun, junB, Krox 20, Krox 24, and c-fos in bovine aortic EC
(BAEC) (11, 35). Similarly, o-HA induced a rapid CD44-
dependent activation of multiple isoforms of PKC (, , and ),
Raf-1 kinase, MEK-1, and ERK1/2 resulting in mitogenesis in
these cells (31). These limited studies have so far failed to
identify all of the key intermediates involved in transduction of
the o-HA-induced mitogenic and wound recovery responses in
vascular EC. This information could be important in the devel-
opment of novel therapeutic strategies for treatment of angio-
genic diseases. In this study, an extension of our findings from
previous work (31), we have examined in detail rapid up-reg-
ulation of associated signaling proteins and have characterized
the pathways responsible for o-HA-induced angiogenesis.
EXPERIMENTAL PROCEDURES
Materials—Primary monoclonal antibodies to H-Ras, anti-phospho-
tyrosine (PY99), and phospho-ERK-1/ERK-2 (pERK1/2), polyclonal an-
tibodies, and their specific blocking peptides against Gi/o/t/z, Gs/olf,
Gq/11, G, PLC1, PLC2, PLC1–3, PLC1, PKC, PKC1–2, PKC,
Sos, Shc, and -actin as well as mouse B cell lymphoma cell lysate
(WEHI-231) were obtained from Autogen Bioclear (Wiltshire, United
Kingdom). PKC isoform-specific inhibitors (Go 6976 and PKC translo-
cation inhibitor peptide), H-Ras inhibitor FTI-277, Gq protein inhibitor
GP antagonist-2A, Gi/o inhibitor pertussis toxin, and PP2 Src family
inhibitor were from Calbiochem. Manufacture of phosphorothioate an-
tisense and matching sense oligonucleotides directed to bovine PKC
was by VHBio (Newcastle-upon-Tyne, UK). Antisense, matching scram-
bled, and FITC-labeled oligonucleotides directed against bovine
PKC1-2 and H-Ras were from Biognostik (Gottingen, Germany). Ras
and ERK activity assay kits, as well as the Src substrate peptide
(KVEKIGEGTYGVVYK), mouse monoclonal anti-Src family tyrosine
kinase, and anti-phospho-Src antibodies were all from Upstate Biotech-
nology (Buckingham, UK). Thermanox plastic coverslips were from
Nunc (Naperville, IL), ECL and ECL plus kits were from Amersham
Biosciences (Bucks, UK) and the protein detection reagent was obtained
from Bio-Rad. All other materials and chemicals were from Sigma.
Preparation of o-HA—The method of preparation is described in full
elsewhere (14). Briefly, native rooster comb HA (500 mg) was dissolved
in sodium acetate buffer (50 ml, 0.1 M, pH 5.4) containing 0.15 M NaCl
and treated with 20,000 units of bovine testicular hyaluronidase at
37 °C. After 2, 4, 6, 8, and 24 h, aliquots (10 ml) were treated with 1 ml
of trichloroacetic acid. Mixtures were centrifuged, and supernatants
were dialyzed against distilled water for 24–48 h at 4 °C in Spectra-Por
tubing (Pierce-Warriner, Chester, UK) with at least 4 changes. They
were then re-centrifuged and lyophilized. The powder was dissolved in
20 ml of 0.1% acetic acid and applied to a G50 Sephadex column (2.6 
180 cm). Fractions (10 ml) were collected, assayed for uronic acid, and
combined to yield three pools (F1, F2, and F3). The size range of
oligosaccharides in each pool was determined after incorporation of
[3H]glucosamine-labeled HA, SDS-PAGE, and fluorography, as de-
scribed previously (14). Successive bands differed on SDS gels by one
disaccharide unit, and precise definition of the size range was deter-
mined by comparison with labeled octa-, hexa-, and tetrasaccharides of
known molecular size. F1, F2, and F3 fractions consisted of disaccha-
ride units of 16, 10–16, and 3–10, i.e. of approximately 7200, 4500–
7200, and 1350–4500 Da, respectively. Angiogenic activity was deter-
mined by adding freeze-dried samples of each fraction onto the
chorioallantoic membrane of the chick embryo. Only fraction F3 (o-HA)
produced a consistent angiogenic response (14, 36) and was used in this
study. Angiogenic activity resided only in the hyaluronate fragments,
because the activity of hyaluronan preparations digested with dena-
tured hyaluronidase and a 24-h normal digest were found to lack
biological activity, suggesting that there was no contamination with
vascular permeability factor. Fraction F3 was further digested with
Streptomyces hyaluronidase, and lost its biological activity, as deter-
mined by the chorioallantoic membrane of the chick embryo assay (14).
Isolation and Routine Culture of BAECs—BAEC were obtained and
characterized as endothelial by the presence of von Willebrand factor
and the uptake of Dil-labeled acetylated low density lipoprotein, as
described previously (12). They were routinely cultured in Dulbecco’s
modified Eagle’s medium containing 15% fetal calf serum, 1.5 mM
glutamine, 100 IU/ml penicillin, and 50 ng/ml streptomycin (complete
medium). Culture flasks were maintained at 37 °C in a humidified
atmosphere of 5% CO2 and 95% air.
Cell Proliferation Studies—BAEC were seeded at a concentration of
2  104/ml in 2 ml of complete medium, in triplicate 6-well plates. After
attachment, medium was replaced with serum poor medium (SPM),
containing 2.5% fetal calf serum in which the cells grew at a signifi-
cantly reduced rate (31). In some cases, specific enzyme inhibitors,
pertussis toxin (10–500 ng/ml, 6 h), Go 6976 (1–100 nM, 24 h), -trans-
location inhibitor (ti, 1–20 , 24 h), FTI 277 (100 nm to 5 M, 24 h),
GP Ant-2A (100 nM-25 M, 4 h), PP2 (10 nM TO 10 M), or sense/
antisense oligonucleotides directed toward PKC/ and H-Ras (10 M,
72 h) were added before incubation with o-HA (1 g/ml) for a further
72 h. Control wells contained appropriate concentrations of the vehicle
(Me2SO or ethanol). Concentration ranges and preincubation times of
inhibitors were based on previously published information and our own
unpublished pilot studies.2 Trypan blue exclusion studies confirmed
that the inhibitors were not cytotoxic to cells at the concentrations
tested (data not included) and wells treated with inhibitors without
o-HA were included as controls. Fresh medium and inhibitors were
added every 72 h where necessary. After 72 h, cells were washed in
PBS, detached in 0.05% trypsin/PBS, and counted on a Coulter counter
(Coulter Electronics, Hialeah, FL) set to a threshold of 30 m. Statis-
tical significance was determined by one-way analysis of variance.
Wound Recovery Assays (Cell Migration)—Semiconfluent cells cul-
tured on Thermanox plastic coverslips in 24-well plates were grown to
confluence in SPM (24–48 h). Medium was replaced with Dulbecco’s
modified Eagle’s medium containing 0.1% fetal calf serum and cells
were incubated for a further 48 h with or without inhibitors/antisense
reagents, in triplicate, as described above. Coverslips were washed in
PBS, the cellular layer wounded using a mechanical wounder (37),
rinsed again in PBS to remove loose and dislodged cells, and placed into
a fresh 24-well plate containing inhibitors or the appropriate vehicles.
Some coverslips were immediately fixed in 100% ethanol (time zero
controls). o-HA (0.5 g/ml) was added to some of the wells and the plate
was incubated at 37 °C for 18 h. Pilot studies demonstrated that BAEC
wounded under these conditions underwent negligible proliferation up
to 24 h (even in the presence of o-HA), however, cell movement resulting
in wound closure was almost complete in cells treated with o-HA at this
concentration after 18 h (native HA had no effect, data not shown). The
coverslips were rinsed (3) in PBS, fixed in 100% ethanol (5 min), and
allowed to air dry. The mechanical wounder produced 11 parallel le-
sions 400-m wide across the cell monolayer. Movement of cells into the
denuded area was quantified using a Seescan computerized image
analysis system (Manchester, UK). Each field of view covered 2% of
the total coverslip area. For each coverslip, 10 fields of view (each 2
mm by 1.45 mm) were examined at random. The lesion area in each
field of view was measured and using the data from time 0 (T0), the
wound area was then converted to give mean % recovery from 3 iden-
tically treated coverslips (%r) using the equation: %r  [1  (wound
area at Tt/wound area at T0)]  100. Where Tt is the wounded area 18 h
post-injury. Statistical significance was determined by one-way analy-
sis of variance.
Intracellular Delivery of Inhibitory Antibodies—Semiconfluent
BAEC were cultured in 6-well plates in SPM for 48 h and the medium
was replaced with Ca2- and Mg2-free bicarbonate buffer (pH 7.3)
containing glycerol (1.2 M) at 37 °C (38, 39). Cells were placed immedi-
ately on ice for 10 min and the plasma cell membrane made transiently
permeable by addition of chilled L--lysophosphatidylcholine (40 g/ml)
for a further 7 min. Pre-warmed SPM (1 ml, 37 °C), containing 5 g of
rabbit anti-mouse control IgG, FITC-labeled IgG, or antibodies to
PLC1–2, PLC1–3, Gi/o/t/z, G, Gs/olf, or Gq/11 was added and the
cells were incubated at 37 °C for a further 1 h. Cells regained their
2 M. Slevin, S. Kumar, and J. Gaffney, unpublished data.
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impermeability during this phase as determined by the recovery of
trypan blue exclusion (data not shown). Uptake and cytoplasmic ex-
pression of antibodies after 1 h was confirmed by fluorescent microscopy
of FITC-labeled cells, using a Leitz microscope (Leica, Bensheim,
Germany) and the appropriate filter, and by FACS analysis (FACScan,
BD Biosciences) following washing (PBS), trypsinization, and fixation
of cells in 4% formaldehyde, PBS. After a 1-h recovery, o-HA (1 g/ml,
5 min) was added to some of the wells that were then washed in PBS
and cell lysates were collected in 0.5 ml of ice-cold radioimmunoprecipi-
tation (RIPA) buffer containing 10 mM Tris-HCl (pH 7.5), 50 mM NaCl,
0.5% sodium deoxycholate, 0.5% (w/v) Nonidet P-40, 0.1% SDS, 1 mM
Na3VO4, and 5 g/ml aprotinin (40). After sonication, lysates were
centrifuged (10,000  g, 15 min at 4 °C) and the supernatants were
collected and stored at 70 °C.
Use of Antisense Oligonucleotides—Phosphorothioate oligonucleo-
tides corresponding to bovine PKC12 and H-Ras were synthesized
by Biognostik (GmbH, Gottingen, Germany) using R.A.D.A.R sequence
design. Sequences of antisense nucleotides for PKC12 were 5-
TCAGCTGGAATCTAAATG and matched scrambled sense/FITC-la-
beled nucleotides were 5-ACTACTACACTAGACTAC (41), whereas H-
Ras antisense nucleotides were 5-GCTTATACTCCGTCATTG and
matched sense nucleotides were 5-GTTACTGCCTCATATTCG (42).
Antisense and control sense oligonucleotides directed toward bovine
PKC were synthesized by VHBio (Newcastle upon Tyne, UK). Anti-
sense sequences were 5-GTCCCTCGCCGCCTCCTG-3 and sense, 5-
GTCCTCCGCCGCTCCCTG-3 as described elsewhere (43). Semicon-
fluent BAEC were cultured at 37 °C in 24-well plates in SPM with or
without oligonucleotides (10 M/72 h) together with LipofectAMINE
2000 (Invitrogen, 10 g/ml). Cell lysates were collected at 4 °C in RIPA
buffer (300 l) and processed as described previously (31). Delivery of
oligonucleotides into the cell cytoplasm was monitored by addition of
FITC-labeled PKC oligonucleotides (10 M, 4–72 h) to semiconfluent
BAEC cultured on glass coverslips in SPM. Pilot studies were carried
out to optimize the effects of oligonucleotides, and showed a notable
reduction in specific protein expression determined by Western blot-
ting, after 72 h exposure to 10 M antisense oligonucleotide.
Western Blotting—Semiconfluent BAEC cultured in 6- or 24-well
plates in SPM (48 h) were incubated with specific enzyme inhibitors or
oligonucleotides before addition of o-HA (1 g/ml, 2–10 min) as de-
scribed previously. Total cell lysates were collected in RIPA buffer and
processed as described earlier, whereas plasma cell membrane and
cytoplasmic fractions were separated using a digitonin-based buffer
system (31). Briefly, after washing in ice-cold PBS, cells in 6-well plates
were agitated at 4 °C for 5 min in 300 l/well of ice-cold buffer contain-
ing 140 mM NaCl, 25 mM KCl, 5 mM MgCl2, 2 mM EDTA and EGTA, 10
g/ml leupeptin and pepstatin, 1 mM phenylmethylsulfonyl fluoride, 20
mM Tris-HCl (pH 7.5), and 0.5 g/ml digitonin (44). The buffer, now
containing the cytoplasmic contents was removed and stored at 4 °C.
The remaining “membrane” fraction was again rinsed in ice-cold PBS
and solubilized in 300 l of the same buffer containing 1% (w/v) Triton
X-100. Both fractions were centrifuged (10,000  g, 15 min at 4 °C) to
remove insoluble debris, and stored at 70 °C. Complete separation of
cytoplasmic and membrane fractions was demonstrated using the lac-
tate dehydrogenase assay. Protein concentration of cell lysates was
determined using a modification of the Bradford assay (Bio-Rad) and
equal quantities of protein (15 g) were mixed with 2 Laemmli sample
buffer, vortex mixed, and boiled in a water bath for 15 min. Samples
were separated along with prestained molecular weight markers
(32,000–200,000) by 12% SDS-PAGE. Proteins were electroblotted
(Hoefer, Bucks, UK) onto nitrocellulose filters (1 h) and the filters were
blocked for 1 h at room temperature in TBS-Tween (pH 7.4) containing
5% (w/v) de-fatted milk (PKC antibodies) or containing 1% (w/v) bovine
serum albumin (all other antibodies). Filters were stained with the
following primary antibodies diluted in the appropriate blocking buffer,
overnight at 4 °C on a rotating mixer: rabbit polyclonal anti-PLC1–2,
PLC1–3, PLC1 (1:500); Gi/o/t/z, G, Gs/olf, Gq/11 (1:750); PKC,
PKC1–2, PKC (1:100); H-Ras (1:400), Shc and Sos (1:1000); mouse
monoclonal antibodies to pERK1/2, Src, and phospho-Src (1:1000); phos-
photyrosine PY99 (1:1500), and phospho-myelin basic protein (1:1500).
After washing (5 10 min in TBS-Tween at room temperature), filters
were stained with either goat anti-rabbit or rabbit anti-mouse horse-
radish peroxidase-conjugated secondary antibodies diluted in TBS-
Tween containing 5% (w/v) de-fatted milk (1:1000, 1 h, room tempera-
ture) with continuous mixing. After a further 5 washes in TBS-Tween,
proteins were visualized using ECL chemiluminescent detection.
Antibody Specificity Studies—Equal concentrations of protein (15
g) from cell lysates were resolved in duplicate by 12% SDS-PAGE as
described above. Polyclonal antibodies (1 g/ml) were incubated with or
without matching blocking peptides specific for a particular epitope
(Santa Cruz) (10 g/ml) overnight at 4 °C on a rotating mixer. Antibod-
ies were then diluted in the appropriate blocking buffer, and identical
blots were stained with antibody, with or without peptide treatment
using the method described previously. Specificity of Src antibodies was
assessed by comparing staining in total BAEC extracts separated by
Western blotting (as described above) with positive control cell lysates
(WEHI-231). We have previously characterized all remaining antibod-
ies (31).
Immunoprecipitation Studies—Equal concentrations of protein from
total cell lysates (100 g in 0.5 ml of RIPA buffer) were incubated with
2 g of primary antibody overnight at 4 °C on a rotating mixer. Anti-
bodies were then attached to protein A/G-agarose beads (20 l, 30 min,
4 °C with continuous mixing). Alternatively, cell lysates were mixed
directly with antibodies already conjugated to protein-agarose beads
(Shc, PLC1, 20 l, overnight, 4 °C). The beads were pelleted by cen-
trifugation (13,000  g/10 min, 4 °C), the supernatant was removed,
and the pellet washed 3 in ice-cold RIPA buffer (0.5 ml). Excess buffer
was removed from the beads and protein-antibody complexes were
solubilized in 50 l of 2 Laemmli sample buffer and subjected, in
duplicate, to 12% SDS-PAGE followed by blotting as described previ-
ously. One of the blots was stained with the original immunoprecipi-
tating primary antibody to confirm equality of protein loading.
Determination of ERK1/2 Activity—The assay kit was supplied by
Upstate Biotechnology, and the protocol was as per the manufacturers
instructions. Briefly, semiconfluent BAEC, cultured in 6-well plates in
SPM (48 h), were treated with the appropriate enzyme inhibitors or
neutralizing antibodies as described earlier, prior to addition of o-HA (1
g/ml, 5 min). ERK1/2 was immunoprecipitated from the cell lysates,
attached to an agarose complex, and then incubated with a substrate
mixture containing myelin basic protein. After SDS-PAGE, blots were
stained with anti-myelin basic protein antibody and developed using
ECL plus.
Determination of Ras Activity—Based on the method described pre-
viously (30), semiconfluent BAEC cultured in 6-well plates in SPM (48
h) were incubated with the appropriate enzyme inhibitors/oligonucleo-
tides described earlier, prior to addition of o-HA (1 g/ml, 2–10 min).
Cells were lysed in 500 l of a Mg2 buffer (pH 7.5) containing 25 mM
HEPES, 150 mM NaCl, 1% Igepal Ca-630, 10 mM MgCl2, 1 mM EDTA,
2% glycerol, 10 g of leupeptin and aprotinin, and 1 mM sodium or-
thovanadate on ice. After centrifugation (10,000  g/20 min, 4 °C) to
remove insoluble material, 500 g of each sample was incubated with
10 l of Raf-1 RBD-agarose conjugate overnight at 4 °C on a rotating
mixer. Beads containing activated Ras were centrifuged (13,000  g/10
min at 4 °C), the supernatant was removed, and the beads were washed
3 in 0.5 ml of the same buffer. Protein complexes were solubilized by
boiling (5 min) in 50 l of 2 Laemmli sample buffer and separated by
12% SDS-PAGE. Resulting blots were blocked for 1.5 h in TBS-Tween
containing 5% defatted milk and stained overnight with monoclonal
anti-H-Ras antibody (RAS10, 1:1000) diluted in the same buffer (4 °C
with constant mixing). Washing, secondary horseradish peroxidase an-
tibody staining, and protein visualization were carried out as described
for the Western blots above. 10 g of the original cell lysate was stained
with anti-H-Ras monoclonal antibody and served as a control to show
total Ras content of each sample.
Determination of Src Activity—Semiconfluent BAEC cultured in
SPM for 48 h in 6-well plates were treated with o-HA (1 g/ml) for 2, 5,
and 10 min or for 8 min, after preincubation for 24 h with PP2 (100 nM)
or pertussis toxin (100 ng/ml). Src was immunoprecipitated in RIPA
lysates under nondenaturing conditions with anti-Src monoclonal anti-
body (2 g/sample, overnight at 4 °C). Bound Src was attached to
protein A/G-agarose beads (20 l/sample, 30 min, 4 °C) and the beads
subsequently washed (1) with RIPA buffer and then (3) with Src
kinase reaction buffer containing 100 mM Tris-HCl (pH 7.2), 125 mM
MgCl2, 25 mM MnCl2, 2 mM EGTA, 0.25 mM sodium orthovanadate, and
2 mM dithiothreitol. Samples were incubated at 30 °C in 15 l of kinase
buffer containing 25 M ATP, 1 g/sample of Src substrate peptide, and
10 Ci of [-32P]ATP as described previously (45). The reaction was
terminated by addition of 20 l of 2 Laemmli sample buffer, the
samples were boiled for 5 min, and proteins were separated by SDS-
PAGE. Incorporated radioactivity was visualized by autoradiography of
the dried gel. Active Src kinase enzyme (Upstate Biotech) was used as
a positive control in pilot experiments used to optimize the protocol.
Analysis of Relative Protein Concentrations—Semiquantitative
analysis of protein concentration from Western blots was carried out
using a scanning densitometer (Amersham Biosciences). Results ac-
companying the figures are given as numerical increase or decrease
compared with the control untreated cells, which were assigned an
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FIG. 1. Involvement of PLC in o-HA-induced signaling. A, Western blot detected expression of the 1, 1, 2, and 1 isoforms of PLC in
BAEC with (, lane 2) and without (, lane 1) neutralizing peptide treatment. B, membrane translocation of PLC1 was observed in Western blots
within 2 min (lanes 2–4, left panel). Translocation of 1 and 2 isoforms was more transient, reaching a maximum after 5 min (lane 3, middle and
right panels). C, Western blots showed an increase in antiphosphotyrosine staining of PLC1 (in PLC1 immunoprecipitates) increasing after 2,
5, and 10 min treatment with o-HA (1 g/ml) (lanes 2–4). Total PLC1 expression demonstrates equality of loading and a comparison with pERK1/2
expression together with -actin loading control is shown in the same samples. D, BAEC were made transiently permeable with L--lysophos-
phatidylcholine and loaded with FITC-labeled IgG antibodies. Delivery was monitored by (i) fluorescent microscopy where  represents
permeabilized cells, and (ii) FACS analysis where M1 represents the fluorescent intensity beyond which 95% of the control cells were negative. E,
BAEC, preloaded with anti-PLC1, antibodies (5 g/ml) reduced o-HA (1 g/ml, 5 min), and induced pERK1/2 expression and activity (lane 3). All
experiments were carried out at least three times and a representative example is shown. WB, Western blot. MBP, myosin basic protein.
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arbitrary optical density of 1.0. The intensity of staining between
different gels could not be compared because of variation in ECL
development time.
RESULTS
As a continuation of our previous work (31), we studied in
detail the up-regulation (between 2 and 10 min) of key signal-
ing proteins and their role in mediating ERK1/2 activation,
proliferation, and cell migration (wound recovery).
Involvement of PLC Isoforms in o-HA Signaling—Western
blot analysis of BAEC extracts showed expression of PLC1,
1, 2, and 1 (Fig. 1A). Disappearance of these proteins in
antibody mixtures pretreated with specific peptides that
blocked the antibody epitope confirmed their identity. Cyto-
plasm to plasma membrane translocation of PLC isoforms is
usually associated with their activation (46, 47). o-HA (1 g/
ml)-treated BAEC showed a rapid increase (within 2 min and
FIG. 2. Specific isoform inhibitors of PKC affect o-HA-induced signal transduction, mitogenesis, and wound recovery. A, Go 6976
(100 nM), and B, TI (20 M) inhibited plasma membrane translocation of PKC, 1, 2, and , respectively, in o-HA (1 g/ml, 5 min)-treated cells
(lane 3). C, preincubation with Go 6976 (100 nM/24 h) reduced o-HA (1 g/ml, 5 min)-induced pERK1/2 expression and activity (lane 3). D, Go 6976
(100 nM) significantly inhibited o-HA (1 g/ml)-induced cell proliferation over 72 h. E, Go 6976 strongly inhibited o-HA (0.5 g/ml/18 h)-induced
wound healing (lane 6, *, p 	 0.01), whereas TI had a much weaker, but still significant effect (lane 5, *, p 	 0.05). In the bar chart, the first
unfilled bar denotes cells with 100% re-growth and the second bar (T0) shows totally denuded, freshly wounded cells. All experiments were carried
out at least three times and a representative example is shown. WB, Western blot. MBP, myosin basic protein.
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maintained after 5 and 10 min) in plasma membrane expres-
sion of PLC1, and more transiently (maximal after 5 min), in
PLC1 and 2 (Fig. 1B). An increase in phosphotyrosine stain-
ing (Tyr(P)-99) of anti-PLC1 immunoprecipitates also oc-
curred within 2 min of treatment (Fig. 1C). We next examined
the involvement of PLC isoforms in ERK1/2 activation. L--
FIG. 3. Effect of antisense reagents on PKC-induced signaling and cell growth. A, shows oligonucleotide (PKC control sequence-FITC)
incorporation into BAEC over 0–72 h. Uptake was observed after 24 h (panel 3). B, BAEC exposed to specific PKC and 1/2 antisense
oligonucleotides (lane 3) (10 M, 72 h), showed protein down-regulation compared with cells treated with scrambled control oligonucleotides (lane
2) and untreated cells (lane 1). C, after antisense treatment, BAEC were exposed to o-HA (1 g/ml, 5 min). A reduction in pERK1/2 expression was
seen in the presence of PKC (left panel, lane 3), and to a lesser extent PKC1/2 (left panel, lane 4) antisense oligonucleotides. D, antisense
down-regulation of PKC protein expression significantly reduced o-HA-induced cell proliferation (*, p 	 0.05). E, PKC1/2 antisense treatment
significantly inhibited wound recovery (lane 7, *, p 	 0.05). In the bar chart, the first unfilled bar denotes cells with 100% re-growth, whereas the
second bar (T0), shows freshly wounded, maximally denuded cells. All experiments were repeated at least three times and the figure shows a
representative example. WB, Western blot.
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higher levels of FITC-labeled IgG than nonpermeabilized cells,
as shown by fluorescent microscopy and FACS analysis (Fig.
1D, i and ii, respectively). Degradation of loaded antibodies
occurred after about 4 h making this technique unsuitable for
long term studies (data not shown). Only anti-PLC1 (5 g/ml)
reduced the o-HA (1 g/ml, 5 min)-induced pERK1/2 formation
(74 and 80%) and ERK activity (70%), respectively, compared
with IgG control antibodies. (Fig. 1E). These results suggest
that o-HA-induced signaling through PLC1 may be primarily
involved in stimulating mitogenesis.
Role of PKC Isoforms in o-HA-induced Mediation of ERK1/2
Activation, Mitogenesis, and Wound Recovery in BAEC—We
showed previously that o-HA-induced ERK1/2 activation, and
subsequent mitogenesis, were partially dependent on activa-
tion and associated plasma membrane translocation of PKC,
-1, -2, and - (31). Pilot studies based on previous published
data (48) showed that Go 6976 (100 nM/24 h preincubation)
reduced plasma membrane translocation of PKC, -1, and -2
(84, 73, and 90%, respectively) but not  after addition of o-HA
(1 g/ml, 5 min). Similarly, the -translocation inhibitor (TI,
20 M/24 h preincubation) attenuated o-HA-induced plasma
membrane translocation of PKC (71%), but had no effect on
PKC, -1, or -2 (Fig. 2, A and B) (49). The inhibitors were not
cytotoxic as shown by cell growth assays in SPM and trypan
blue exclusion. Only Go 6976 (100 nM/24 h) notably reduced
o-HA-induced formation of pERK1/2 (75 and 73%, respectively)
and ERK activity (78%) compared with untreated cells (Fig.
2C). Pretreatment with Go 6976 significantly inhibited o-HA-
induced cell proliferation (70%) compared with untreated cells
(p 	 0.05) although TI had no inhibitory effect (Fig. 2D).
Similarly, the presence of Go 6976 almost completely inhibited
o-HA-induced wound healing (p 	 0.001), although TI had a
much smaller (18%) but still significant effect (p 	 0.05, Fig.
2E).
To distinguish between the functional importance of PKC
and - isoforms, BAEC were exposed to specific antisense or
scrambled oligonucleotides. Fluorescent monitoring of FITC-
labeled scrambled PKC showed appreciable cytoplasmic incor-
poration over 24–72 h (Fig. 3A). Addition of PKC antisense
reagent (10 M) with LipofectAMINE 2000 (10 g/ml), to semi-
confluent BAEC, resulted in down-regulation in PKC protein
expression after 72 h (55%) without affecting 1, 2, or 
isoforms, compared with the controls. PKC1/2 antisense rea-
gent (10 M) produced 70 and 75% reduction in expression of
those isoforms, respectively, without affecting PKC or - (Fig.
3B). Antisense inhibition of PKC reduced pERK1/2 expression
in o-HA (1 g/ml, 5 min)-treated cells (73 and 72%, respective-
ly), whereas PKC inhibition resulted in a smaller reduction
(41 and 37%, respectively) (Fig. 3C). Scrambled oligonucleo-
tides had no effect on pERK1/2 expression. Incorporation of
PKC antisense oligonucleotide also significantly reduced
o-HA-induced BAEC proliferation by 49% (p 	 0.05, analysis of
variance) but only weakly inhibited wound recovery (15% p 	
0.05) (Fig. 3, D and E, respectively). Treatment with PKC
antisense oligonucleotide had no effect on proliferation, but
strongly inhibited o-HA-induced wound recovery (85%, p 	
0.001). In conclusion, the  isoform may be more important in
regulating mitogenesis through ERK1/2, whereas the  iso-
forms, and to a lesser extent , are primarily involved in cell
migration/wound recovery.
Activation of Ras in o-HA-treated BAEC: Role in Cell Mito-
genesis and Wound Healing—Ras activity increased 5.5-fold
within 2 min, and remained higher than control levels 10 min
after o-HA treatment (1 g/ml) (Fig. 4A). Analysis of total Ras
expression indicated equality of protein loading. Pilot studies
using FTI-277, a potent and specific inhibitor of Ras farnesyl-
transferase processing (50), showed an optimum inhibitory con-
centration that avoided cellular cytotoxicity of 1 M over 24 h.
BAEC pretreated with FTI-277 before addition of o-HA (1 g/
ml, 5 min) showed a 71% reduction in Ras activity (Fig. 4B), as
well as the degree of pERK1/2 formation (62 and 74%, respec-
tively) and ERK activity (83%) (Fig. 4C). A significant reduc-
tion in both o-HA-induced cell proliferation and wound recov-
ery occurred in the presence of FTI-277 (51%, p	 0.05, Fig. 4D,
and 63%, p 	 0.05, Fig. 4E, respectively). To confirm these
findings, Ras protein was down-regulated using specific Ras
antisense oligonucleotides. Pilot studies showed exposure of
BAEC cultured in SPM to 10 M antisense oligonucleotides
with 10 g/ml LipofectAMINE 2000 reduced Ras protein ex-
pression by 70% after 72 h compared with sense controls (Fig.
5A). o-HA (1 g/ml, 5 min)-induced activation of Ras, measured
in Raf-1 kinase RBD-agarose immunoprecipitates, was reduced
FIG. 4. Inhibition of o-HA-induced Ras activation by FTI-277
reduces BAEC mitogenesis and wound recovery. A, BAEC showed
an increase in active Ras expression within 2 min of o-HA (1 g/ml)
treatment (lanes 2–4). Total Ras expression is shown as a loading
control. B, FTI-277 (1 M, 24 h) inhibited o-HA (1 g/ml, 5 min)-induced
Ras activation (lane 3). C, o-HA (1 g/ml, 5 min)-induced pERK1/2
expression and activity were markedly reduced in FTI-277 (1 M, 24 h)-
treated cells (lane 3). -Actin loading controls are also shown. D, o-HA
(1 g/ml)-induced BAEC proliferation was significantly reduced after
72 h (*, p 	 0.05) in the presence of FTI-277 (1 M). E, FTI-277 (1 M,
24 h) significantly inhibited o-HA (0.5 g/ml, 18 h)-induced wound
recovery (lane 5, *, p 	 0.05). In the bar chart, the first unfilled bar
denotes cells with 100% re-growth, whereas the second bar (T0) shows
freshly wounded, maximally denuded cells. All experiments were re-
peated at least three times and shows a representative example. WB,
Western blot. MBP, myosin basic protein.
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by 72% (Fig. 5B), whereas pERK1/2 formation decreased by 31
and 33%, respectively, in antisense-treated BAEC (Fig. 5C).
BAEC cultured with antisense reagent in the presence of o-HA
demonstrated a significant reduction in cell proliferation after
72 h (55%, p 	 0.05, Fig. 5D), and wound recovery after 18 h
(62%, p	 0.05, Fig. 5E), compared with sense controls. Neither
Go 6976 nor PKC antisense reagents notably reduced Ras
activity (data not shown), suggesting Ras activation was inde-
pendent of PKC.
Involvement of G-proteins in o-HA-induced Signal Transduc-
tion—Little is known of the mechanisms through which o-HA
receptors initiate second messenger activation. Because we
have demonstrated activation of several isoforms of PLC, we
examined the involvement of heterotrimeric G-proteins in this
process. BAEC expressed the Gi/o/t/z, G subunit (after o-HA
treatment 1 g/ml, 5 min), Gs/olf and Gq/11 subtypes (Fig. 6A).
Antibodies treated with peptide inhibitors () served as nega-
tive controls to confirm expression of the protein and specificity
FIG. 5. Down-regulation of Ras protein using antisense reagents reduces o-HA-induced signal transduction and angiogenesis in
BAEC. A, BAEC exposed to Ras antisense oligonucleotides (left panel, lane 2, 10 M, 72 h) showed a reduction in Ras protein expression compared
with control sense-treated cells (right panel). B, cells stimulated with o-HA (1 g/ml, 5 min) after Ras antisense treatment showed a reduction in
activation of Ras protein (left panel, lane 3). -Actin protein loading controls are also shown. C shows a reduction in pERK1/2 expression in cells
treated as in B above (lane 4). D, antisense treatment was sufficient to significantly reduce o-HA (1 g/ml, 72 h)-induced cell proliferation, and E,
o-HA (0.5 g/ml, 18 h)-induced wound recovery (lane 5) (*, p 	 0.05, in both cases). In the bar chart (E), the first unfilled bar denotes cells with
100% re-growth and the second bar (T0) shows freshly wounded, maximally denuded cells. All experiments were repeated at least three times and
shows a representative example. WB, Western blot.
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of the antibodies. Cytoplasmic loading of either anti-Gi/o/t/z or
anti-G (5 g/ml as described earlier) inhibited o-HA (1 g/ml,
5 min)-induced pERK1/2 expression (66 and 62% and 74 and
68%, respectively) and ERK activity by 70 and 75%, respec-
tively (Fig. 6B), whereas anti-Gs/olf and Gq/11 had no inhibi-
tory effect. Activation of G proteins causes their translocation
from the plasma membrane to the cytoplasm together with
formation of both G and G subunits, the G subunits
remaining plasma membrane-bound (51). Gi/o/t/z proteins
were detected in the cytoplasmic fraction and G subunits in
the membrane fraction, within 2 min, in o-HA (1 g/ml)-treated
BAEC (Fig. 6C). Pretreatment of BAEC with the specific
Gi/o protein inhibitor pertussis toxin (52) (100 ng/ml, 6 h),
reduced o-HA (1 g/ml, 5 min) induced cytoplasmic expression
of Gi/o/t/z proteins by 65%, and appearance of G subunits in
the membrane fraction by 95% (Fig. 6D). No cellular cytotox-
icity was found at this concentration. Pretreatment of BAEC
with pertussis toxin markedly reduced o-HA (1 g/ml, 5 min)
induced PKC, -1, and -2 membrane translocation (92, 55,
and 77%, respectively, Fig. 7A), pERK1/2 expression (50 and
FIG. 6. o-HA induces activation of pertussis toxin-sensitive G-proteins in BAEC. A, expression of Gi/o/t/z, Gs/olf, Gq/11, and G subunits
(after o-HA treatment 1 g/ml, 5 min) in BAEC was demonstrated by Western blotting (WB). Confirmation of specificity is shown by the
disappearance of the protein band in specific inhibitory peptide-treated antibody mixtures (shown as , lane 2). B, cell cytoplasm loading of
antibodies to either Gi/o/t/z (lane 3) or G subunits (lane 4) inhibited o-HA-induced
pERK1/2 expression and ERK activity. C shows appearance of
G subunits in the membrane fraction (right panel) and Gi/o/t/z in the cytoplasmic fraction (left panel) within 2 min in o-HA (1 g/ml)-treated cells
(lanes 2–4). D, preincubation of cells with pertussis toxin (P.toxin) (100 ng/ml, 6 h) inhibited o-HA-induced (1 g/ml, 5 min) redistribution and
separation of G-proteins (lane 3). All experiments were repeated at least three times and a representative example is shown. MBP, myosin basic
protein.
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55%, respectively) and activity (51%) (Fig. 7B). Pertussis toxin
at the same concentration significantly inhibited both prolifer-
ation (72 h) and wound recovery (18 h) of BAEC (66%, p	 0.05,
Fig. 7C and 47%, p 	 0.05, Fig. 7D, respectively), compared
with vehicle-only treated cells. o-HA-induced Ras activation
was not affected in pertussis toxin-treated cells (Fig. 7E), sug-
gesting it acts on a separate pathway. When the previous
experiments were repeated using the specific Gq inhibitor GP
ant-2A (53), there was no demonstrable effect on o-HA-induced
mitogenic or wound healing responses (data not shown). These
results suggest that activation of Gi/o proteins in o-HA-treated
BAEC is at least in part responsible for control of tyrosine
kinase-associated events resulting in mitogenesis and wound
healing. We next performed co-precipitation studies to identify
possible binding partners for Gi/o proteins and G() subunits.
There was no association between Gi/o/t/z and G subunit
immunoprecipitates from o-HA (1 g/ml, 2, 5, and 10 min)-
treated cells, and PLC1, -2, or -3 (data not shown). How-
ever, G subunits co-precipitated with PLC1 within 2 min
(Fig. 8A), and this was reduced by 80% after preincubation of
BAEC with pertussis toxin (Fig. 8B). Tyrosine phosphorylation
of PLC1 was also partially inhibited by 64% following prein-
cubation with pertussis toxin in o-HA-treated cells (Fig. 8C).
Finally, preincubation with the Src kinase inhibitor PP2 (100
nM, 24 h), reduced PLC1 association with G subunits (90%)
in G immunoprecipitates (Fig. 8D). These results suggest a
role for G protein regulation independent of Ras in a distinct
signal transduction pathway.
o-HA Activates Ras via Src and Subsequent Mobilization of
Shc in BAEC—Previous work has demonstrated that both re-
cruitment to and interaction of Src with CD44 following HA
binding promoted cell migration in human ovarian tumor cells
(SK-OV-3 ipc) (54). Activation of Src is one mechanism through
which the adapter protein Shc can stimulate Ras. Specificity of
Src antibodies was determined by comparison with staining in
a control whole cell lysate (WEHI-231, Fig. 9A). Activation
(within 5 min) and tyrosine phosphorylation (within 2 min) of
Src lasted up to 10 min in o-HA (1 g/ml)-treated BAEC (Fig.
9B). The Src family kinase inhibitor PP2, used at the optimum
inhibitory concentration of 100 nM/24 h (determined from pilot
studies), reduced tyrosine phosphorylation and activation of
Src in o-HA (1 g/ml, 5 min)-treated BAEC (68 and 88%,
respectively, Fig. 9C). Pretreatment of BAEC with pertussis
toxin had no effect (Fig. 9D), suggesting that upstream activat-
ing components may not include heterotrimeric G proteins.
Preincubation of BAEC with PP2 before addition of o-HA (1
and 0.5 g/ml, respectively), resulted in a significant decrease
in cell proliferation after 72 h (65%, p 	 0.05, Fig. 10A), and
wound recovery after 18 h treatment (82%, p 	 0.05, Fig. 10B).
PP2 also inhibited activation of Ras (53%, Fig. 10C), pERK1/2
FIG. 7. Pertussis toxin inhibits o-HA-induced signal transduc-
tion and mitogenesis. A, BAEC pretreated with pertussis toxin
(P.toxin) (100 ng/ml, 6 h) reduced plasma membrane translocation of
PKC, 1, and 2 isoforms in the presence of o-HA (1 g/ml, 5 min)
(lane 3). B, pretreatment of BAEC with pertussis toxin also inhibited
o-HA-induced pERK1/2 expression and ERK activity (lane 3), as well as,
C, cell proliferation after 72 h (*, p 	 0.05). D, o-HA (0.5 g/ml,
18 h)-induced wound recovery was significantly reduced in the presence
of the toxin (lane 5, *, p 	 0.05). In the bar chart, the first unfilled bar
denotes cells with 100% re-growth, and the second bar (T0) shows
freshly wounded maximally denuded cells. E, shows the inability of
pertussis toxin to inhibit Ras activity in o-HA (1 g/ml, 5 min)-treated
cell lysates processed as described previously (lane 3). All experiments
were repeated at least three times and the above shows a representa-
tive example. WB, Western blot. MBP, myosin basic protein.
FIG. 8. G subunits co-precipitate with PLC: sensitivity to
both pertussis toxin and PP2. A, immunoprecipitated G subunits
co-precipitated with PLC1 within 2 min of o-HA (1 g/ml) treatment
(lanes 2–4). B, preincubation of BAEC with pertussis toxin (P.toxin)
(100 ng/ml, 6 h) reduced o-HA (1 g/ml, 5 min)-induced association of
G subunits with PLC1 in G immunoprecipitates (lane 3). C, the
same treatment also reduced o-HA (1 g/ml, 5 min)-induced phospho-
rylation of PLC1 (lane 3). D, preincubation of cells with PP2 (100 nM/24
h) also inhibited o-HA (1 g/ml, 5 min)-induced G subunit co-precipi-
tation with PLC1 (lane 3), measured in G immunoprecipitated cell
lysates. All experiments were repeated at least three times and the
shows a representative example. WB, Western blot.
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formation (70 and 56%, respectively), and ERK activity (82%,
Fig. 10D), suggesting that it could be an essential upstream
component. We attempted to identify the mechanism through
which c-Src induced activation of Ras. Ras activation commonly
occurs following ShcSosGrb2 complex formation, after auto-
phosphorylation of tyrosine kinase receptors and subsequent
dimerization (55). Shc tyrosine phosphorylation may also be
dependent on Src (54). BAEC expressed both the p60 and p66
isoforms of Shc, with specificity being determined by peptide
inhibition studies (Fig. 11A). Anti-Shc immunoprecipitates
from o-HA (1 g/ml)-treated cells showed an increase in tyro-
sine phosphorylation of both p60 and p66 isoforms within 2 min
(Fig. 11B), which was reduced by 65% following preincubation
of cells with PP2 (Fig. 11C). Shc co-precipitated with Src within
2 min of o-HA (1 g/ml) treatment (Fig. 11D), and this was
reduced in the presence of PP2 (91 and 72% respectively, Fig.
11E). Shc did not co-precipitate with heterotrimeric G proteins,
G subunits, or PLC1 (data not included).
Many receptors activate the Ras-MAP kinase pathway fol-
lowing redistribution and phosphorylation of the adapter pro-
tein Shc and its subsequent association with the SosGrb2
complex (55). BAEC expressed Sos2 (p170), specificity of the
antibody being confirmed using inhibitory peptides (Fig. 11F).
Co-precipitation studies showed o-HA-induced association of
Sos2 with Shc after 2 min of treatment (Fig. 11G).
DISCUSSION
Knowledge of the mechanisms through which HA stimulates
angiogenesis will help understand its central role in tissue
remodeling and the pathobiology of diseases such as rheuma-
toid arthritis, diabetic retinopathy, psoriasis, neoplasia, and
stroke. We have previously shown that o-HA-stimulated second
messenger activity in BAEC involved PKC and MAP kinase
(ERK1/2), and resulted in mitogenesis (31). Native, high mo-
lecular weight HA that is anti-angiogenic in vivo had no effect
on signal transduction activity, proliferation, or wound recov-
ery in these cells, but inhibited activation by o-HA (3, 11, 35),
making BAEC an appropriate and relevant model for the study
of the action of o-HA on vascular EC. In this study we show
rapid o-HA-induced phosphorylation and membrane transloca-
tion of PLC1, which is the natural activator of PKC (56).
Cytoplasmic incorporation of anti-PLC1 antibodies resulted in
a notable reduction in ERK1/2 activation, suggesting a role for
PLC1 in regulation of mitogenesis. PLC 1 and 2 isoforms,
although transiently translocated, had no effect on ERK1/2
activity. Other studies have shown that mobilization of PLC
isoforms could be associated with heterotrimeric G-protein in-
volvement in the signaling process (57).
Cytoplasmic introduction of inhibitory antibodies to either
Gs/olf or Gq/11 had no effect on o-HA-induced ERK1/2 activity,
suggesting that adenyl cyclase-associated and pertussis toxin-
insensitive pathways were not involved (57). Furthermore, al-
though the specific Gq/11 enzyme inhibitor, GP ant-2A (53),
attenuated bombesin-induced pERK1/2 expression in our cell
system, it had no effect on o-HA-induced signaling or mitogen-
esis.2 We found a rapid increase in expression of G subunits in
the plasma membrane and Gi/o/t/z in the cytoplasmic fraction
of o-HA-treated cells. Cytoplasmic introduction of antibodies to
either of these proteins reduced ERK1/2 activity, suggesting
the involvement of pertussis toxin-sensitive G-proteins. Forma-
tion of G() subunits as well as their cell compartmentaliza-
tion is a feature of their activation (50), and can result in
FIG. 9. o-HA induces activation of Src family kinase which is
sensitive to PP2. A shows expression of the Src family kinase in BAEC
(lane 2), compared with a positive control cell lysate (lane 1). B, o-HA (1
g/ml)-induced phosphorylation and activation of Src within 5 min of
treatment (lanes 2–4). Total Src expression is shown as a loading
control. C shows PP2 (100 nM, 24 h) inhibition of o-HA (1 g/ml, 5
min)-induced activation and tyrosine phosphorylation of Src (lane 3). E
shows that preincubation of BAEC with pertussis toxin (P.toxin) (100
ng/ml, 6 h) had no effect on o-HA (1 g/ml, 10 min)-induced Src activa-
tion or tyrosine phosphorylation of proteins (lane 3). All experiments
were repeated at least three times and shows a representative example.
WB, Western blot.
FIG. 10. PP2 inhibits o-HA-induced signal transduction and
mitogenesis in BAEC. A, PP2 (100 nM, 24 h) significantly inhibited
o-HA (1 g/ml)-induced cell proliferation after 72 h (*, p 	 0.05). B, PP2
(100 nM for 24 h) significantly inhibited o-HA (0.5 g/ml, 18 h)-induced
wound recovery (lane 5, *, p 	 0.05). In the bar chart, the first unfilled
bar denotes cells with 100% re-growth and the second bar (T0) shows
freshly wounded maximally denuded cells. C, PP2 at the same concen-
tration inhibited by o-HA (1 g/ml, 5 min)-induced Ras activation (lane
3), as well as D, pERK1/2 formation and ERK activity (lane 3). All
experiments were repeated at least three times and shows a represent-
ative example. WB, Western blot. MBP, myosin basic protein.
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complex formation and activation of multiple isoforms of PLC
(57). Other studies have shown the ability of G dimers to
activate phosphoinositol-3-kinase resulting in cell proliferation
and survival, usually involving activation of the transcription
factor NF-B (58, 59). Although HA fragments can also activate
NF-B in some human carcinoma cell lines (30), our unpub-
lished data2 showed that phosphoinositol-3-kinase was not ac-
tivated by o-HA in BAEC, and furthermore, that wortmannin,
a specific inhibitor of phosphoinositol-3-kinase (60), had no
effect on o-HA-induced signaling events. We demonstrated co-
precipitation of G subunits with PLC1 after o-HA treatment,
and also that inhibition of Gi/o proteins using pertussis toxin
was sufficient to inhibit phosphorylation of PLC1, plasma
membrane translocation of PKC isoforms, and ERK1/2 activity.
Cell proliferation and wound recovery were also attenuated
suggesting that the association of G with PLC1 has an im-
portant role in o-HA-induced cell signaling. Other studies have
described an association between PLC1 and Gi proteins in
BAEC resulting in PLC1 activation (61). This association
usually occurred in the presence of another tyrosine kinase-
activated co-precipitant such as Src kinase. For example, in
human embryonic intestinal epithelial cells, leukotriene D4
induced co-precipitation of G subunits with PLC. This in-
teraction was blocked by PP2, suggesting that physical associ-
ation of Src with PLC after agonist stimulation could result in
PLCG complex formation (62). Similarly, agonist activa-
tion of Src kinase in a variety of cell lines was sensitive to
pertussis toxin indicating a role for Gi-coupled receptors (63).
In this study, we showed a rapid increase in tyrosine phospho-
rylation (within 2 min), and activation (within 5 min) of the Src
family kinase in o-HA-treated cells. The importance of Src
activation was demonstrated by a significant reduction in
o-HA-induced proliferation and wound recovery in PP2-treated
cells, whereas preincubation with PP2 reduced o-HA-induced
GPLC1 complex formation, suggesting that Src might be a
necessary component of PLC1 activation. We could not, how-
ever, show direct association of Src with PLC1. Furthermore,
pertussis toxin did not inhibit activation of Src, suggesting its
activation was independent of heterotrimeric G-proteins.
Inhibition of ERK1/2 activity by PP2 prompted us to inves-
tigate possible downstream signaling intermediates. Ras is a
key enzyme necessary for activation of the Raf-1 kinase-Mek-
MAP kinase pathway in response to a variety of ligand-receptor
interactions, resulting in mitogenesis and oncogenesis (64).
Activation of Ras by native HA in rat embryonic fibroblasts
(3Y1) (29), and by o-HA in a CD44- and PKC-dependent man-
ner in human T24 bladder carcinoma cells, has previously been
demonstrated (30). We show an o-HA-induced increase in Ras
activity within 2 min, whereas ERK1/2 activity, cell prolifera-
tion, and wound recovery were inhibited by the Ras farnesyl-
transferase inhibitor FTI-277 and Ras antisense reagent. Ac-
tivation of Ras was independent of heterotrimeric G proteins
and PKC, because neither pertussis toxin nor Go 6976 were
inhibitory. Also, the direct PKC activator phorbol 12,13-dibu-
tyrate was unable to activate Ras.2
Conventional growth factor receptor activation of Ras in-
volves phosphotyrosine-dependent association of Shc with an
autophosphorylated receptor (51). The subsequent interaction
between phosphorylated Shc and the adapter protein Grb2
causes membrane translocation of the Grb2Sos complex where
Sos mediates guanine nucleotide exchange on Ras (65). Release
of G subunits from pertussis toxin-sensitive heterotrimeric
G-proteins can also result in tyrosine phosphorylation of Shc
and induction of Grb2Sos complex formation (52) or
ShcGrb2Src complex formation (57). In this study, Shc became
tyrosine phosphorylated within 2 min of treatment with o-HA,
and furthermore, co-precipitated strongly with Src. PP2 treat-
ment was sufficient to reduce Shc tyrosine phosphorylation,
complex formation between Src and Shc, and subsequent Ras
activity. Finally, we demonstrated co-precipitation of Shc with
Sos, suggesting that o-HA activates Ras through Src-depend-
ent activation of Shc-Grb2-Sos. This mechanism of Ras activa-
tion has previously been described following treatment of
human epidermoid carcinoma cells (A431) with (S)-12-
hydroxyeicosatetraenoic acid (54).
Elsewhere, we have shown that plasma membrane translo-
cation and activation of PKC, 1, 2, and  were important in
formation of pERK1/2 and cell mitogenesis (31). We have ex-
amined the function of these isoforms in more detail. Activation
of ERK1/2 and mitogenesis occurred mainly through PKC,
whereas PKC1/2 had a much weaker effect but was necessary
for efficient wound recovery in o-HA-treated cells. Other au-
thors have highlighted the importance of PKC in mediating
cell proliferation induced by phorbol esters in rat microvessel
FIG. 11. o-HA induces Src-dependent mobilization of Shc and
its association with Sos. A, expression of Shc (p60/p66) is shown in
BAEC lysates, with (, lane 2) or without (, lane 1) specific inhibitory
antibody blocking peptide. B, tyrosine phosphorylation of Shc was in-
creased within 2 min treatment with o-HA (1 g/ml) in Shc immuno-
precipitates (lanes 2–4). C, PP2 (100 nM, 24 h) reduced o-HA (1 g/ml,
5 min)-induced Shc tyrosine phosphorylation (lane 3). D, shows co-
precipitation of Src within 2 min of treatment with o-HA (1 g/ml)
following Western blotting of Shc immunoprecipitates (lanes 2–4). E,
o-HA (1 g/ml, 5 min)-mediated co-precipitation of Src with Shc was
inhibited in the presence of PP2 (100 nM/24 h) (lane 3). F, expression of
Sos 2 (p170) in BAEC lysates. Specificity of the antibody was shown
following disappearance of the band after treatment with epitope bind-
ing inhibitory peptide (, lane 2). G, co-precipitation of Shc with Sos 2
occurred within 2 min of o-HA treatment in Sos immunoprecipitates
(lanes 2–4). All experiments were carried out at least three times and a
representative example is shown.
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EC (67), and in vascular endothelial growth factor-treated hu-
man umbilical vein EC (68). Similarly, a role for PKC in
regulation of cell migration, in human coronary smooth muscle
cells induced by high glucose (69), and in porcine vascular
smooth muscle cells treated with insulin-like growth factor
(70), has been described. Promotion of cell movement through
activation of PKC may involve its localization to specific mi-
crotubule-organizing centers and microtubules in the cytoskel-
eton (71). HA-induced motility of Ras-transformed 10T1/2 (C3)
fibroblasts in a PKC-dependent manner that was also associ-
ated with rapid uptake of HA by both CD44 and RHAMM
receptors (72). Our own data2 has shown that inhibitors of
tyrosine phosphorylation (genistein) and Mek-1 (PD98059)
were sufficient to reduce wound recovery, suggesting these
signaling pathways are also important.
Here we have described for the first time, the signaling
mechanisms through which o-HA stimulates angiogenesis in
vascular EC (see Fig. 12). At least two distinct pathways con-
verge upstream of the MAP kinase resulting in cell activation.
Heterotrimeric G-proteins and in particular, release of G()
subunits seem to be important in mediating PLC1 activation
of PKC, whereas separately, Src family kinases activate Ras
through ShcGrb2Sos complex formation. The pathways may
overlap because PP2 inhibited G association with PLC1.
Identification of the interactions between HA receptors and
their primary second messengers should be the focus of further
studies. More than one potentially important HA cell surface
receptor has been described in vascular EC. We have previ-
ously shown expression of the CD44 receptor in BAEC and its
role in promotion of o-HA-induced tyrosine phosphorylation
(31). Other studies have reported a similar response to o-HA in
human glioma cells (73), whereas association of CD44 with Src
was shown in human neutrophils (74) and human ovarian
tumor cells (53) after treatment with o-HA. Expression of
RHAMM was demonstrated on the cell surface of a variety of
primary human vascular EC (33). Both native HA and in par-
ticular o-HA treatment, resulted in RHAMM-dependent tyro-
sine phosphorylation and MAP kinase activation, suggesting
that this was the functional HA receptor. Src activity has also
been associated with RHAMM-mediated cell motility in mouse
fibroblasts (26). Other EC-specific receptors such as white
fat-HA binding protein, detected in human aorta and atherec-
tomy samples (76), have also been identified, although their
importance in mediation of HA-induced signal transduction
has not been determined. Our results leave open the possibility
that more than one o-HA-specific receptor may be present on
the surface of BAEC. The mechanism through which o-HA (F3
fragments) binds to receptors and activates angiogenesis in
both our in vivo and in vitro models should be examined in
detail. Whereas other authors have demonstrated the ability of
native HA to weakly activate signal transduction activity as-
sociated with proliferation in vascular EC of different origin
(33), different sized fragments of HA may elicit specific re-
sponses in individual cells for a variety of reasons. For in-
stance, it may depend on the types of receptor expressed, the
operational signal transduction pathways available (which
may work in synergy as described in this work), and also on the
ability of the molecule to specifically interact with the appro-
priate link module binding site on the receptor (77). The data
presented here may be useful in the identification of potential
targets for modulation of angiogenesis in a variety of diseases
associated with abnormal EC growth.
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